ANXA2P2: A Drug Target / Disease Biomarker (G304)

Target Name: ANXA2P2

NCBI ID: G304

ANXA2P2

Other Name(s): ANX2P2 | annexin A2 pseudogene 2 | ANX2L2 | Annexin A2 pseudogene 2 | LPC2B

ANXA2P2: A Drug Target / Disease Biomarker

ANXA2P2, also known as ANXA2P2R, is a protein that is expressed in the brain and is involved in several cellular processes. It has been identified as a potential drug target for the treatment of several psychiatric and neurological disorders, including anxiety, depression, and schizophrenia.

ANXA2P2 is a member of the ANXA2P2 gene family, which is known for its role in the development and progression of several psychiatric and neurological disorders, including anxiety and depression. The ANXA2P2 gene has been shown to be associated with increased risk of developing these disorders, and research has suggested that ANXA2P2 may play a role in their pathophysiology.

ANXA2P2 is involved in several cellular processes that are important for brain development and function. It is a key regulator of the migration of neurons, which is a critical process for the development and organization of the nervous system. It is also involved in the production and release of neurotransmitters, such as dopamine and GABA, which are important for mood and cognitive function.

ANXA2P2 has been shown to be involved in the development of several psychiatric and neurological disorders. For example, research has shown that ANXA2P2 levels are increased in the brains of individuals with major depressive disorder (MDD), and that inhibition of ANXA2P2 has been shown to improve symptoms of MDD.

In addition, ANXA2P2 has also been shown to be involved in the pathophysiology of other psychiatric and neurological disorders, including anxiety and schizophrenia. For example, research has shown that ANXA2P2 levels are increased in the brains of individuals with anxiety disorders, and that inhibition of ANXA2P2 has been shown to improve symptoms of anxiety.

Given the involvement of ANXA2P2 in several cellular processes that are important for brain function, it is a promising target for the treatment of psychiatric and neurological disorders. Research is currently being conducted to determine the efficacy of ANXA2P2 as a drug treatment for these disorders.

In conclusion, ANXA2P2 is a protein that is expressed in the brain and is involved in several cellular processes that are important for its development and function. It has been identified as a potential drug target for the treatment of several psychiatric and neurological disorders, including anxiety, depression, and schizophrenia. Further research is needed to determine its efficacy as a drug treatment.

Protein Name: Annexin A2 Pseudogene 2

Functions: Calcium-regulated membrane-binding protein whose affinity for calcium is greatly enhanced by anionic phospholipids. It binds two calcium ions with high affinity. May be involved in heat-stress response

The "ANXA2P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANXA2P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets